Brink Therapeutics SAS

Brink Therapeutics SAS is a biopharmaceutical company focused on developing innovative therapies targeting chronic diseases through personalized medicine and advanced drug formulations. Brink Therapeutics SAS, founded in 2024 by CEO Jonathan Naccache and CTO Harry Kemble, in Saint-Mande, France, specializes in biopharmaceutical solutions and has successfully completed 1 deal to date. The company raised USD 3. 500 mn in Seed funding on April 16, 2025, with investments from Breega, Kima Ventures, Kurma Partners, and Plug and Play Ventures.

The founder's background and previous ventures are not publicly detailed. Brink Therapeutics specializes in developing innovative biopharmaceutical solutions aimed at addressing unmet medical needs in various therapeutic areas. Their core product offerings focus on advanced therapies designed for the treatment of chronic diseases, with an emphasis on personalized medicine. The company aims to improve patient outcomes through the development of drug formulations that leverage proprietary technologies.

Brink Therapeutics primarily targets healthcare providers, hospitals, and specialty clinics, serving both adult and pediatric populations in North America and select markets in Europe. Their products are rigorously tested to ensure safety and efficacy, providing solutions for patients suffering from complex health conditions. Brink Therapeutics generates revenue through direct-to-consumer sales and partnerships with healthcare institutions. The company employs a subscription model for certain services, allowing ongoing access to its therapeutic products for healthcare providers and their patients.

Strategic partnerships with pharmaceutical companies may also be engaged for co-developing and distributing products. Pricing structures are established based on product and service nature, including tiered pricing for bulk purchases by healthcare providers. The company’s flagship products contribute significantly to its overall financial health. Brink Therapeutics plans to leverage the recent Seed funding of USD 3.

500 mn to recruit researchers and validate five therapeutic recombinases for gene and cell therapy applications. Upcoming initiatives include launching new products designed for chronic disease management, with specific release dates yet to be announced. The company targets expansion into additional European markets and North America by 2026, aiming to broaden its reach and enhance service delivery for healthcare providers.